Tag Archives: consumers

  • Consolidation Activity in the Generic Sector

    … developed to assume that products will remain available to consumers at the right price. As producers drop out, monopolies are developed and the Federal Trade Commission is obliged to step in to protect competition and consumer choice.  This involves its own level of management which can also put stress on the company to deliver products to the consumer. So beneath the economic/business surface news of an acquisition/there’s the underlying practical considerations which may be overlooked …

  • SCG’s thoughts on the last 10%

    For the Pharmaceutical industry, it is difficult for consumers to tell the difference between an excellent, acceptable or poor quality product.  For this reason, safety, quality and reliability problems can go undetected  until the FDA detects them during an inspection or after investigation for a product recall.  By then, the problems can be out of control and can result in a Warning Letter or Consent Decree. The below excerpt can be found here: “ // // Seth’s Blog: The …

  • Lean Biomanufacturing: Keeping Your Eye on the Quality Goal

    … going to hurt our companies and the industry as well. Lean manufacturing in medical products, which should include but need not necessarily be limited to pharmaceuticals, vaccines, biotechnology products and medical devices is all about producing the highest quality products for consumers. As already noted, this is frequently missed out when one talks about Lean because out culture is often heavily geared towards the efficiency component. This is naturally understandable in a highly competitive …

  • Growing Cooperation between Big Pharma and Patients

    … innovation to the payer-provider relationship, the botton line is, they still have to make money.  Because of ever increasing competition from oversees, not to mention increasing price pressures and growing market access restrictions, this process is proving far more difficult than previously imagined. While both sides are working hard to come up with the best solution, the common consensus is that starting a healthy dialogue is key.  Through this healthy dialogue consumers as well as the …

  • Is the Pharmaceutical Industry Going Green?

    … just creating cheaper, natural solvents in their place.  This is not only saving drug companies millions of dollars in development and distribution, but is potentially saving its consumers of potentially hazardous, cancer- causing chemicals, as well as sustaining an environmentally responsible attitude that hopefully will lead the way for other pharmaceutical and manufacturing companies for decades to come. If you liked this article, tell all your friends about it. They’ll thank you for …

  • AAI, CONSUMER GROUPS ENCOURAGE CONGRESS TO BAN PATENT SETTLEMENTS AND RESTORE COMPETITION IN MARKET FOR GENERIC DRUGS

    Seven of the leading consumer groups in the United States, the American Antitrust Institute, consumers Union, Families USA, The National Legislative Association on Prescription Drug Prices, Consumer Federation of America, US PIRG and Community Catalyst wrote to Speaker Pelosi and Majority Leader Reid asking Congress to include a per se ban on reverse payments in the revised healthcare reform legislation. Here is the official press release from AAI AAI, CONSUMER GROUPS ENCOURAGE CONGRESS TO BAN …

  • The Global Vaccines Market, 2008-2023

    … of the current epidemic patterns and healthcare needs. The most important reason for the growth of vaccines is that they are extremely cost effective in fighting disease, thus, governments and private health providers will increasingly encourage their use. There is increased awareness now in terms of  the benefits of preventive medicine relative to  the better quality of life and reduction of healthcare costs for consumers, and the vaccine industry is answering the call with new products, and …

  • Looking for Money in New Places

    … field, which is completely neglected by the big pharmaceutical companies.  There are also the organizations dedicated to a specific disease that are very interested in funding promising research directed towards their field of concern. The future prospects for the biotech industry are positive.  The consumers are still spending money on its products, and the interest of big pharma companies in the new technologies developed by biotech firms is very strong.  Life sciences consulting companies …

  • How Bioscience Companies are Using Social Media to Reach Key Audiences

    … better relationships with their consumers.  But is social media really an effective marketing tool for large pharmaceutical companies? And why now are they starting to jump on the social media bandwagon, after years of resistance? As the economic downturn continues to adversely affect pharmaceutical companies all over the world, many pharmaceutical consultants are starting to recommend giving social media a try.  Until recently, much of the pharmaceutical industry has shied away from entering …

  • Importation Law and Mandatory FDA Inspections

    Not too long ago, a bipartisan group of senators in the United States introduced legislation that could spell big problems for the pharmaceutical industry.  The “Pharmaceutical Market Access and Drug Safety Act” is a piece of legislation being pushed through the Senate to immediately reduce drug prices for consumers, which will ultimately force the Bio-Pharma Industry to have to drastically reduce the price of drugs here in the United States.  According to the Congressional Budget …

  • Scenarios For Health Care Reform

    … though the pharmaceutical companies support health care reform, they may not be eagerly supporting a nationalized health care plan.  A nationalized plan, although unlikely at this point, could cut prescription drugs up to 15% even to 30% if the national plan offers very little choice for consumers.  Under this worst case scenario for the pharmaceutical industry, they could see their stock values fall up to 40%.  Any pharmaceutical consultant will tell you this scenario is unlikely, but it is …

  • U.S. Falls Behind Europe in Research and Drug Development

    … consumers. European research and development isn’t nearly as costly compared to the high cost of patent-protected drugs in the U.S. – this is where the U.S. falls short. The study examined new chemical entities (NCEs) from 1982 through 2003. These drugs (NCEs) are introduced to the world’s largest markets. The study focused on the percentage of drug research funds to the percentage of NCEs credited to the U.S., Europe and Japan.  Each area of research was measured for productivity. The …